Functional Coronary Angiography Guided Revascularization in STEMI - Trial NCT05818475
Access comprehensive clinical trial information for NCT05818475 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital of Ferrara and is currently Recruiting. The study focuses on Myocardial Infarction. Target enrollment is 1800 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Hospital of Ferrara
Timeline & Enrollment
N/A
May 08, 2023
May 08, 2028
Primary Outcome
Primary Efficacy Outcome: Patient Oriented Composite Outcome,Primary Safety Outcome: Major Bleeding and Contrast - Associated Acute Kidney Injury
Summary
The goal of this multicenter randomized clinical trial is to test the superiority in terms of
 efficacy of the Angiography-derived fractional flow reserve (AIR) over that based on
 conventional angiography (ANGIO) strategy in the management of non-culprit lesions in STEMI
 patients with multivessel disease.
 
 The main questions it aims to answer are:
 
 - is an Angiography-derived fractional flow reserve strategy superior to a conventional
 angiography strategy in reducing the occurrence of the composite efficacy endpoint of
 all-cause death, myocardial infarction, cerebrovascular accident, or ischemia-driven
 revascularization.
 
 - is an Angiography-derived fractional flow reserve strategy superior to a conventional
 angiography strategy in reducing the occurrence of the composite safety endpoint of of
 contrast-associated acute kidney injury and Bleeding Academic Research Consortium (BARC)
 type 3-5.
 
 Participants will be randomized after the successful treatment of the culprit lesion to one
 of the two strategies and prospectively followed-up.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05818475
Non-Device Trial